Breast neoplasms, Cannabinoid receptor 2 (CB2), Cannabinoid/s, Disease Progression, Down-Regulation, ErbB-2, Female, Human, Neoplasm Metastasis, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt/antagonists & inhibitors, Receptor/s

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

Background: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also...

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.